Email: cspc@cspc.cn
Media
News Center
Jun. 01
2026
PHASE III CLINICAL STUDY RESULTS OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2-P
May. 29
ENNITUO (ANBENITAMAB INJECTION) RECEIVES MARKETING AUTHORISATION FROM NMPA
May. 26
VOLUNTARY ANNOUNCEMENT - LANSOPRAZOLE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
May. 22
VOLUNTARY ANNOUNCEMENT - USTEKINUMAB INJECTION RECEIVES MARKETING AUTHORISATION FROM NMPA
May. 21
VOLUNTARY ANNOUNCEMENT - BUDESONIDE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
May. 11
VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESO
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
